Specifically, previous reports have proposed that pan-D2 inhibition or BRD4/BRD2 combination inhibition have been more suitable as anti-inflammatory strategies. However, we have shown that compounds 2 and 3 (BRD4-D1 and pan-D1 biased, respectively) show efficacy in reducing key inflammatory markers and necrotic area in liver injury models. Further, we demonstrate that selective inhibition of BRD4-D1 can serve as an effective strategy but is likely limited to micromolar ranges due to cellular permeability.